49619-82-1

Basic information

• Product Name: 3-BROMOCHROMONE
• Synonyms: 3-BROMOCHROMONE;3-BROMO-4H-CHROMEN-4-ONE;3-Bromochromone,97%;3-BROMOCHROMONE 97%;3-Bromochromone, (3-Bromo-4H-chromene-4-one);3-Bromo-4-oxo-4H-1-benzopyran;3-Bromo-4H-1-benzopyran-4-one
• CAS NO: 49619-82-1
• Molecular Formula: C₉H₅BrO₂
• Molecular Weight: 225.04
• Product Categories: Chromones;Benzopyrans;BenzopyransHeterocyclic Building Blocks;Building Blocks;Halogenated Heterocycles;Heterocyclic Building Blocks
• Mol File: 49619-82-1.mol

Chemical Properties

• Melting Point: 94-98 °C(lit.)
• Boiling Point: 269.5 °C at 760 mmHg
• Flash Point: 116.8 °C
• Appearance: /
• Density: 1.738 g/cm₃
• Vapor Pressure: 0.00724mmHg at 25°C
• Refractive Index: 1.655
• Storage Temp.: Inert atmosphere,Room Temperature
• BRN: 125684
• CAS DataBase Reference: 3-BROMOCHROMONE(CAS DataBase Reference)
• NIST Chemistry Reference: 3-BROMOCHROMONE(49619-82-1)
• EPA Substance Registry System: 3-BROMOCHROMONE(49619-82-1)

Safety Data

• Statements: 36/37/38
• Safety Statements: 26-36/37/39
• WGK Germany: 3
• Hazardous Substances Data: 49619-82-1(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
3-Bromochromone is used as a chemical intermediate for the synthesis of various pharmaceutical compounds. Its presence in the chromone family suggests potential applications in the development of drugs with anti-inflammatory, anti-viral, and anti-cancer properties.
Used in Chemical Research:
3-Bromochromone is used as a subject of study in chemical research, particularly in the field of medicinal chemistry. Its unique structure and potential reactivity make it an interesting candidate for exploring new chemical reactions and syntheses.
Used in Material Science:
3-Bromochromone may be used in the development of new materials with specific properties, such as those with potential applications in electronics or as components in advanced materials. Its reactivity and structural features could contribute to the creation of novel materials with unique characteristics.

InChI:InChI=1/C9H5BrO2/c10-7-5-12-8-4-2-1-3-6(8)9(7)11/h1-5H

Upstream product

• 110-89-4 piperidine 
• 98592-23-5 3,3-dibromo chroman-4-one 
• 60-29-7 diethyl ether 
• 118-93-4 o-hydroxyacetophenone 
• 106129-86-6 1-(2-hydroxyphenyl)-3-dimethylaminoprop-2-enone 
• 7170-38-9 3-phenoxypropanoic acid 
• 491-37-2 2,3-dihydro-4H-1-benzopyran-4-one 
• 17422-74-1 3-Formylchromone 
• 39079-62-4 chromone-3-carboxylic acid 
• 491-38-3 1-benzopyran-4(4H)-one 
• 58264-73-6 (2R,3R)-3-Bromo-2-methoxy-chroman-4-one 
• 4637-24-5 N,N-dimethyl-formamide dimethyl acetal 
• 35572-23-7 (E)-1-(2'-hydroxyphenyl)-3-(piperidin-1-yl)prop-2-en-1-one 
• 58264-72-5 2,3-dibromo-chroman-4-one 

Downstream Products

• 574-12-9 isoflavone 
• 120185-88-8 3-(4-nitrophenyl)-4H-1-benzopyran-4-one 
• 87744-30-7 2-[1-Cyclohexylamino-meth-(Z)-ylidene]-benzofuran-3-one 
• 87744-29-4 2-[1-Benzylamino-meth-(Z)-ylidene]-benzofuran-3-one 
• 1084-62-4 1-(2-hydroxy-phenyl)-3-piperidin-1-yl-propenone 
• 40302-79-2 3-(1-piperidinyl)-4H-1-benzopyran-4-one 
• 115237-37-1 3-[(1E)-2-phenylethenyl]-4H-1-benzopyran-4-one 
• 130735-56-7 2-(4-morpholinyl)-4H-1-benzopyran-4-one 
• 1099596-95-8 methyl 5-(2-hydroxybenzoyl)-2-(2-methoxy-2-oxoethyl)-3-furoate 
• 153000-44-3 3-(3-methoxyphenyl)-4H-chromen-4-one 
• 132351-67-8 3-(4-chlorophenyl)-4H-1-benzopyran-4-one 

Relevant articles and documents

Probing Embryonic Development Enables the Discovery of Unique Small-Molecule Bone Morphogenetic Protein Potentiators

We report on the feasibility to harness embryonic development in vitro for the identification of small-molecule cytokine mimetics and signaling activators. Here, a phenotypic, target-agnostic, high-throughput assay is presented that probes bone morphogenetic protein (BMP) signaling during mesodermal patterning of embryonic stem cells. The temporal discrimination of BMP- and transforming growth factor-β (TGFβ)-driven stages of cardiomyogenesis underpins a selective, authentic orchestration of BMP cues that can be recapitulated for the discovery of BMP activator chemotypes. Proof of concept is shown from a chemical screen of 7000 compounds, provides a robust hit validation workflow, and afforded 2,3-disubstituted 4H-chromen-4-ones as potent BMP potentiators with osteogenic efficacy. Mechanistic studies suggest that Chromenone 1 enhances canonical BMP outputs at the expense of TGFβ-Smads in an unprecedented manner. Pharmacophoric features were defined, providing a set of novel chemical probes for various applications in (stem) cell biology, regenerative medicine, and basic research on the BMP pathway.

Electrochemical C-H Halogenations of Enaminones and Electron-Rich Arenes with Sodium Halide (NaX) as Halogen Source for the Synthesis of 3-Halochromones and Haloarenes

Without employing an external oxidant, the simple synthesis of 3-halochromones and various halogenated electron-rich arenes has been realized with electrode oxidation by employing the simplest sodium halide (NaX, X = Cl, Br, I) as halogen source. This electrochemical method is advantageous for the simple and mild room temperature operation, environmental friendliness as well as broad substrate scope in both C-H bond donor and halogen source components.

Synthesis of 3-halochromones with simple KX halogen sources enabled by: In situ halide oxidation

On the basis of a designated in situ oxidation tactic, the synthesis of 3-halochromones has been realized for the first time by using simple KX (X = Br, I) salts as halogen sources. Instead of the free radical process, the control experiments indicate that the reported reactions proceed through a halogenium intermediate. Compared to the known synthetic methods relying on molecular halogen, haloid acid or N-halosuccinimide as the halogen source, the present method is attractive due to its higher atom economy and being more friendly to the operator, thus providing a practical complimentary approach to the preparation of useful halochromone compounds.

Metal-free, green and efficient oxidative α halogenation of enaminones by halo acid and DMSO

Metal free oxidative halogenation of N-aryl enaminones has been demonstrated using a DMSO-halo acid combination under mild reaction conditions. This strategy allows a facile halogenation of enaminones through α functionalization leading to a broad range o

A Benazepine isoprenoid flavone compound and its preparation method and application

The invention relates to a piperazine ring-containing isoflavone-like compound as well as a preparation method and application thereof. The preparation method comprises the following steps: dissolving2-hydroxyacetophenone and N,N-dimethylformamide dimethy

METHODS FOR PRECISION THERAPEUTIC TARGETING OF HUMAN CANCER CELL MOTILITY AND KITS THEREOF

Disclosed are methods for identifying an agent of interest that alters binding or activity of a client protein to a chaperone and kits thereof.

A domino reaction of 3-chlorochromones with aminoheterocycles. Synthesis of pyrazolopyridines and benzofuropyridines and their optical and ecto-5′-nucleotidase inhibitory effects

A new and efficient domino reaction of 3-chlorochromones with electron-rich aminoheterocycles was developed which allows for a convenient synthesis of a variety of pyrazolo[3,4-b]pyridines, pyrrolo[2,3-b]pyridines, pyrido[2,3-d]pyrimidines and benzofuro[3,2-b]pyridines. The products exhibit strong fluorescence. In addition, they exhibit significant ecto-5′-nucleotidase inhibition properties and cytotoxic behavior.

Precision therapeutic targeting of human cancer cell motility

Increased cancer cell motility constitutes a root cause of end organ destruction and mortality, but its complex regulation represents a barrier to precision targeting. We use the unique characteristics of small molecules to probe and selectively modulate cell motility. By coupling efficient chemical synthesis routes to multiple upfront in parallel phenotypic screens, we identify that KBU2046 inhibits cell motility and cell invasion in vitro. Across three different murine models of human prostate and breast cancer, KBU2046 inhibits metastasis, decreases bone destruction, and prolongs survival at nanomolar blood concentrations after oral administration. Comprehensive molecular, cellular and systemic-level assays all support a high level of selectivity. KBU2046 binds chaperone heterocomplexes, selectively alters binding of client proteins that regulate motility, and lacks all the hallmarks of classical chaperone inhibitors, including toxicity. We identify a unique cell motility regulatory mechanism and synthesize a targeted therapeutic, providing a platform to pursue studies in humans.

Transition-metal-free decarboxylative bromination of aromatic carboxylic acids

Methods for the conversion of aliphatic acids to alkyl halides have progressed significantly over the past century, however, the analogous decarboxylative bromination of aromatic acids has remained a longstanding challenge. The development of efficient methods for the synthesis of aryl bromides is of great importance as they are versatile reagents in synthesis and are present in many functional molecules. Herein we report a transition metal-free decarboxylative bromination of aromatic acids. The reaction is applicable to many electron-rich aromatic and heteroaromatic acids which have previously proved poor substrates for Hunsdiecker-type reactions. In addition, our preliminary mechanistic study suggests that radical intermediates are not involved in this reaction, which is in contrast to classical Hunsdiecker-type reactivity. Overall, the process demonstrates a useful method for producing valuable reagents from inexpensive and abundant starting materials.

INHIBITION OF CANCER CELL MOTILITY

Provided herein are compositions and methods for inhibiting cancer cell motility and/or metastasis. In particular embodiments, KBU2046 (or an analog thereof) and one or more additional therapies (e.g., cancer therapies (e.g., hormone therapies and chemotherapies) are provided to inhibit cancer cell motility, inhibit metastasis, and/or treat cancer (e.g., prostate cancer, lung cancer, breast cancer, colon cancer, etc.).